- Home
- GNS vs ELOX Comparison
GNS vs ELOX Comparison
Compare GNS & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GNS | ELOX |
|---|---|---|
| Founded | 2002 | N/A |
| Country | Singapore | United States |
| Employees | N/A | 7 |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.7M | 43.8M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | GNS | ELOX |
|---|---|---|
| Price | $0.19 | $11.66 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 4.1M | 48.2K |
| Earning Date | 03-09-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $156.26 | N/A |
| Revenue Next Year | $35.38 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.18 | $10.00 |
| 52 Week High | $1.72 | $15.00 |
Technical Indicators
Market Signals| Indicator | GNS | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 40.77 | 38.06 |
| Support Level | $0.18 | N/A |
| Resistance Level | $0.23 | $15.00 |
| Average True Range (ATR) | 0.02 | 2.29 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 29.96 | 27.50 |
Price Performance
Historical ComparisonAbout GNS Genius Group Limited
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. Its revenue is derived from five reportable segments: Central, Academy, School, Resorts, and Discontinued operations. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America.
About ELOX Eloxx Pharmaceuticals Inc. Common Stock
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.